Brainstorm Cell Therptcs Entered Into Securities Purchase Agreement With a Single Institutional Investor >BCLI
Express News | Brainstorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
Express News | Brainstorm Cell Therapeutics Inc - Alignment With FDA on Nur Own Cmc Aspects
Express News | Brainstorm Cell Therapeutics Reaches Alignment With FDA on Cmc Aspects of Phase 3B Nurown® Clinical Trial
BrainStorm Appoints Haro Hartounian as COO
BrainStorm Cell Therapeutics: Hartounian's Appointment Effective June 18 >GHDN.BE
Express News | Brainstorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.d. as Chief Operating Officer
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
12 Health Care Stocks Moving In Monday's Pre-Market Session
Brainstorm Cell Therapeutics (BCLI) Rockets in Afterhours Despite Questions Raised
12 Health Care Stocks Moving In Friday's After-Market Session
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment With NurOwn
Brainstorm Cell Therapeutics | 10-Q: Quarterly report
Brainstorm Cell Q1 2024 Adj EPS $(0.05) Beats $(0.07) Estimate
Press Release: BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Brainstorm Cell Therapeutics Shares Are Trading Lower After the Company Announced It Received a Letter From the Nasdaq Indicating That It Did Not Regain Compliance With the Minimum Bid Price Requirement.
Brainstorm Cell Therapeutics Received Letter From Nasdaq Indicating Co Had Not Regained Compliance With Minimum Bid Price Requirement By April 29
12 Health Care Stocks Moving In Tuesday's After-Market Session
Brainstorm Cell Therapeutics Executive Leadership Changes
BrainStorm Cell Therapeutics Promotes Bob Dagher to Chief Medical Officer